Primary liver cancer spectrum: current knowledge and the next steps.

Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-607/coif). E.K.K. received research funding from Surface Oncology to investigate IL-27 antibody blockade in HCC and is inventor on filed patents not associated with the topic presented in this article. Y.H. serves as an advisor for Helio Genomics, Espervita Therapeutics, Alentis Therapeutics, Roche Diagnostics, and Elevar Therapeutics and he holds shares in Espervita Therapeutics and Alentis Therapeutics. J.D.Y. provides a consulting service for AstraZeneca, Eisai, Exact Sciences, Exelixis, Fujifilm Medical Sciences, and Gilead Sciences. The other author has no conflicts of interest to declare.